Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P49354
UPID:
FNTA_HUMAN
Alternative names:
CAAX farnesyltransferase subunit alpha; FTase-alpha; Ras proteins prenyltransferase subunit alpha; Type I protein geranyl-geranyltransferase subunit alpha
Alternative UPACC:
P49354; A6NJW0; Q53XJ9; Q9UDC1
Background:
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha, known by alternative names such as CAAX farnesyltransferase subunit alpha and FTase-alpha, plays a pivotal role in protein prenylation. This process involves the transfer of farnesyl or geranylgeranyl groups to proteins, crucial for their proper localization and function. The protein is instrumental in the activation of RAC1, a key regulator of neuromuscular junction development.
Therapeutic significance:
Understanding the role of Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha could open doors to potential therapeutic strategies. Its involvement in critical cellular processes like protein prenylation and neuromuscular junction development makes it a promising target for drug discovery efforts aimed at treating neuromuscular disorders.